Related Experiment Videos

The clinical implications of aldosterone escape in congestive heart failure

Allan D Struthers1

  • 1Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. a.d.struthers@dundee.ac.uk

European Journal of Heart Failure
|August 11, 2004
PubMed

Insights

Aldosterone blockers significantly reduce mortality and hospitalizations in heart failure patients, even those on other standard therapies. This is crucial as aldosterone contributes to cardiovascular risks and adverse cardiac remodeling.

Area of Science:

  • Cardiology
  • Endocrinology

Background:

  • Angiotensin converting enzyme (ACE) inhibitor therapy is insufficient to control aldosterone in up to 40% of congestive heart failure (CHF) patients, leading to 'aldosterone escape'.
  • Elevated aldosterone levels are linked to increased cardiovascular event risk.
  • Aldosterone negatively impacts cardiovascular health by promoting endothelial dysfunction, reducing nitric oxide bioavailability, and driving myocardial fibrosis and cardiac remodeling.

Purpose of the Study:

  • To evaluate the impact of aldosterone blockers on mortality and hospitalization in patients with left ventricular dysfunction or CHF.
  • To establish the role of aldosterone inhibition as a standard therapy in specific cardiovascular patient populations.

Main Methods:

  • Analysis of two major prospective trials.
  • Inclusion of patients receiving standard care, including ACE inhibitors and beta blockers.

Main Results:

  • Aldosterone blockers significantly reduced all-cause mortality in patients with acute or chronic left ventricular dysfunction or CHF.
  • Aldosterone blockers significantly decreased sudden cardiovascular death and hospitalisation rates.
  • These benefits were observed even in patients already on ACE inhibitor and beta blocker therapy.

Conclusions:

  • Inhibition of aldosterone's effects via mineralocorticoid receptors is a critical therapeutic strategy.
  • Aldosterone blockers should be considered standard therapy for patients with left ventricular dysfunction or CHF.
  • Targeting aldosterone is essential for mitigating cardiovascular risks and improving outcomes in heart failure.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.